Rocket


News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

CureVac N.V. Create: Alert

All | News | Filings
Date FiledTypeDescription
09/28/2023 6-K Quarterly results
08/17/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2023 and for three and six months ended June 30, 2023 and 2022",
"​"
08/17/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update · Initiated Phase 2 study in COVID-19 with monovalent and bivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSK · Initiated Phase 1study of cancer vaccine candidate, CVGBM, for surgically resected glioblastoma; recruitment of second dose cohort well on track · Broadened position in patent litigations by expanding the scope and asserting new intellectual property rights in Germany and the U.S. · Public hearing held before the Regional Court Düsseldorf as part of German patent litigation against Pfizer/BioNTech · Cash and cash equivalents position of €537.9 mill..."
08/01/2023 6-K Quarterly results
07/14/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"CureVac Announces Update to the Management Team TÜBINGEN, Germany / BOSTON, USA – July 14, 2023 – CureVac N.V. , a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid , today announced that Dr. Igor Splawski, CureVac’ s Chief Scientific Officer, will step down effective July 14, 2023 to return to early-stage research in the United States. During the search for a successor, CureVac’ s Chief Development Officer, Dr. Myriam Mendila, will head the advancement of CureVac’ s unique mRNA technology platform and its integration with the clinical development of novel mRNA vaccines and therapeutics. “We are extremely grateful for Igor’ s many contributions to CureVac’ s research strategy and his vital role in bringing the compa..."
07/13/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights · Cases in Germany and the U.S. broadened by asserting additional, new intellectual property rights · Three new intellectual property rights added to infringement lawsuit against Pfizer/BioNTech in Germany, increasing number of asserted intellectual property rights to eight · Tenth patent added to CureVac’ s counterclaim against Pfizer/BioNTech in the U.S., covering innovations in mRNA purification methods highly relevant to the manufacturing of Comirnaty® TÜBINGEN, Germany – July 13, 2023 – CureVac N.V. , a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid , today announced that it ha..."
05/30/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Convening notice including agenda and explanatory notes",
"Convening notice including agenda and explanatory notes",
"Voting proxy"
05/30/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update"
05/19/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech · Motion to transfer U.S. litigation to Eastern District of Virginia granted at CureVac's request and expected to significantly accelerate U.S. litigation timeline · CureVac is filing counterclaim in U.S. court under nine patents covering foundational mRNA innovations highly relevant to the design, formulation and manufacturing of Comirnaty® · German Federal Patent Court issued preliminary opinion in April 2023 supporting validity of a German patent corresponding to one of the patents enforced against Pfizer/BioNTech in the U.S. TÜBINGEN, Germany – May 19, 2023 – CureVac N.V. , a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic..."
04/25/2023 6-K Quarterly results
03/31/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Final Tabulation Table of Votes Cast on the Company’s Extraordinary General Meeting of Shareholders"
03/29/2023 6-K Quarterly results
02/27/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Convening notice including agenda and explanatory notes",
"Convening notice including agenda and explanatory notes",
"Voting proxy"
02/10/2023 6-K Quarterly results
02/06/2023 6-K Quarterly results
02/01/2023 6-K Quarterly results
01/31/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"CureVac Named as One of the World’ s Most Dynamic Innovators by LexisNexis · CureVac recognized as a Top 100 innovator in acknowledgment of the company’ s innovative strength and extensive intellectual property portfolio · The company holds one of broadest intellectual property portfolios in mRNA technology TÜBINGEN, Germany/ BOSTON, USA – January 31, 2023 – CureVac N.V. , a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid , today announced its inclusion in the second annual “Innovation Momentum: The Global Top 100” report by LexisNexis. The Top 100 recognizes companies advancing innovative solutions to address today’ s challenges and laying the intellectual property foundations for further breakthrou..."
01/30/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs",
"Presentation entitled “Extended Preliminary Phase 1 Data from Joint COVID-19 and Flu mRNA Vaccine Development Programs”"
01/09/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"CureVac Appoints Alexander Zehnder as CEO From April 1, 2023 · Dr. Franz-Werner Haas to complete successful tenure as CEO by March 31, 2023 · Dr. Alexander Zehnder to succeed Dr. Haas as new CEO, joining from Sanofi on April 1, 2023 TÜBINGEN, Germany/ BOSTON, USA – January 9, 2023 – CureVac N.V. , a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid , today announced that after more than 10 years as a member of the CureVac management board and three years as CEO, Dr. Franz Haas will step down as CEO, effective March 31, 2023. Dr. Alexander Zehnder will succeed Dr. Haas, joining from Sanofi on April 1, 2023. “The recent clinical validation of the power of CureVac’ s proprietary mRNA-technology platform r..."
01/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs · Promising COVID-19 and flu modified mRNA vaccine candidates identified based on positive preliminary data from ongoing Phase 1studies · All candidates use CureVac’ s advanced second-generation mRNA backbone optimized to achieve improved mRNA translation and strong immune responses at low doses · The preliminary results provide strong evidence of technology for CureVac’ s mRNA platform; CureVac and partner GSK plan to advance modified mRNA COVID-19 and flu candidates to the next stages of clinical development · COVID-19: monovalent modified mRNA vaccine candidate CV0501, encoding Omicron variant BA.1, successfully boosted antibody titers against BA.1 and ancestral varian..."
12/14/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program TÜBINGEN, Germany/ Boston, USA – December 14, 2022 - CureVac N.V. , a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid , today announced that Chief Executive Officer Franz-Werner Haas, Chief Financial Officer Pierre Kemula and Interim Chief Development Officer Ulrike Gnad-Vogt sold an aggregate of 103,775 CureVac common shares. The sales were made solely to cover tax and social security obligations from a legacy Virtual Stock Option Plan , which granted virtual options to key members of management. The tax obligations arose as a result of option exercises pursuant to the terms of the Prior VSOP. Except for tax obliga..."
11/17/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Unaudited Interim Condensed Consolidated Financial Statements as of September 30, 2022 and for the nine month periods ended September 30, 2022 and 2021",
"​",
"​"
11/17/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update · Delivering on broad second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK o Phase 1studies in influenza and COVID-19 on track to deliver clinical data in Q1 2023 · Strengthening oncology position based on preparations for new clinical studies with mRNA-based cancer vaccine candidates and positive Phase 1 data on CV8102 o Two proof-of-principle studies planned in 2023 to validate and optimize second-generation mRNA backbone in oncology o Phase 1 expansion study of non-coding RNA-based candidate CV8102 confirms safety and strong immuno-modulatory characteristics · First manufacturing licenses..."
08/18/2022 6-K Quarterly results
08/18/2022 6-K Quarterly results
08/18/2022 6-K Quarterly results
07/05/2022 6-K Quarterly results
06/27/2022 6-K Quarterly results
06/22/2022 6-K Quarterly results
06/08/2022 6-K Quarterly results
06/08/2022 6-K Quarterly results
06/01/2022 6-K Quarterly results
05/25/2022 6-K Quarterly results
05/25/2022 6-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy